Roivant Sciences Ltd. is attracting interest from large pharmaceutical companies for its treatment for inflammatory bowel disease, which could be worth more than $7 billion, according to people familiar with the matter.
While deliberations have focused on the treatment, it’s possible the entire company could be sold as well, some of the people said, asking not to be identified because the matter isn’t public. The drug is being tested to treat ulcerative colitis and Crohn’s disease. The interest from large pharmaceutical companies, which are studying a potential purchase of the mid-stage drug, underscores the excitement for potentially lucrative immunology treatments.
There’s no certainty deliberations will result in a deal and Roivant could opt to keep the asset, for now called RVT-3101, the people said.
Read the full story on Bloomberg here.